Pheon Therapeutics: The company raised $68 million of Series A venture funding in a deal co-led by Atlas Venture, Brandon Capital, Brandon Biocatalyst and Forbion on September 28, 2022. Research Corporation Technologies also participated in the round. The company is a developer of Antibody-Drug Conjugate (ADC) intended for a wide range of hard-to-treat cancers.
Kyruus: The company raised $35.1 million of venture funding from undisclosed investors on September 30, 2022. The company is a developer of a SaaS-based administrative data management platform built for healthcare organizations.
Form Bio: The company raised $30 million of Series A venture funding in a deal led by JAZZ Venture Partners on September 27, 2022. Builders VC and 7 other investors also participated in the round. The company is a developer of a biotechnology platform for scientific discovery.
Qnovia: The company raised $24.2 million in Series A venture funding in a deal led by Blue Ledge Capital on September 28, 2022, putting the company’s pre-money valuation at $70 million. DG Ventures, Gaingels, Evolution VC Partners, Vice Ventures and Third Lake Capital also participated in the round. The company is an operator of a biotechnology platform that offers a medicated vape system.
XP Health: The company raised $22.6 million through a combination of Series A venture funding in a deal led by Valor Capital Group, HC9 Ventures and ManchesterStory on September 28, 2022, putting the company’s pre-money valuation at $22.8 million. The company is a developer of an AI-powered vision benefits platform designed for human sight care.
Doccla: The company raised GBP 15 million of Series A venture funding in a deal led by General Catalyst on September 29, 2022. Speedinvest, KHP Ventures and Giant Ventures also participated in the round. The company is a provider of virtual ward services intended to shift patient care from hospitals to the home.
Kupando: The company raised EUR 13 million of Series A venture funding in a deal led by LifeCare Partners and Remiges Ventures on September 26, 2022. Brandenburg Kapital, High-Tech Gründerfonds, Ventura BioMed Investors, and other undisclosed investors also participated in the round. The company is an operator of a biopharmaceutical business intended to provide immunotherapy to cancer patients and prevent infectious diseases.
Cionic: The company raised $12.4 million of Series A venture funding in a deal led by BlueRun Ventures with participation of HealthTech Capital, Caffeinated Capital, JobsOhio Growth Capital Fund, EPIC Ventures, LDV Capital and other undisclosed investors on September 26, 2022. The company is a developer of neural sleeves designed to assist people with the activities of daily living.
ClostraBio: The company raised $9.9 million of venture funding from Mansueto Office, Portal Innovations and other undisclosed investors on September 26, 2022. The company is an operator of a biopharma company intended to develop therapeutics for food allergies.
New Frontier Bio: The company raised $8.9 million of venture funding from undisclosed investors on September 26, 2022. The company is a developer of consumer health products intended to reverse the signs of aging and promote natural health and lifespan on a cellular level.
New View Surgical: The company raised $7.0 million of venture funding from undisclosed investors on September 30, 2022. The company is a developer of a surgical imaging and access system designed for minimally invasive surgery.
Precidiag: The company raised $3 million of venture funding from undisclosed investors on September 26, 2022. The company is a developer of precision therapeutics and complementary diagnostics intended to precisely target pathogens in the gut that cause and/or contribute to disease.
ixCells Biotechnologies: The company received an undisclosed amount of development capital from Great Point Partners on September 29, 2022. The company is a provider of cell biology and technology services intended to help in developing therapeutic drugs and disease models.
